To the editor,
President, Nationwide Breast Most cancers Coalition
Within the July 19 article “Platinum medicine are off the scarcity record, however the underlying downside is unsolved,” FDA Commissioner Robert Califf and others describe an answer to the U.S. drug scarcity as a matter of paying extra for generic medicine.
It’s disappointing that the management of the medical oncology and coverage communities apparently consider that tweaking however in the end perpetuating the prevailing system of drug pricing is the reply to drug shortages.
We shouldn’t be determining how you can pay extra for medicine to extend revenue, however how you can fully revise the system in order that, throughout the board, price relies on actual worth to sufferers.
We must always not proceed to assist a system that deprives sufferers of what could also be lifesaving medicine due to a small revenue margin, nor ought to we countenance low high quality most cancers medicine. There’s something very improper about that method.
The reply isn’t rising the margins or high quality metrics. The reply is an entire new system. These aren’t automobiles, they’re individuals’s lives.
